SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts. The Phase 2a study tested SCY-635 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a difficult to treat population of HCV genotype 1 patients.
The presentation, titled "Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients" will be given by Dr. Andrew J. Muir, lead investigator of the study, beginning at 4:45 ET on November 11th in room 210 at the Hynes Convention Center.
SCY-635 has demonstrated the potential to play an important role in the reversal of immune exhaustion, or as an Immune Acting Antiviral, in difficult to treat patients with HCV.
The trial was a randomized, placebo-controlled, double-blind study with the primary objective of evaluating the effect of treatment with SCY-635 in combination with PegIFN α-2a and RBV on HCV viral replication in treatment-naive subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.
ADAMTS13 deficiency drives platelet accumulation in pyrrolizidine alkaloid-induced liver injury